Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Goldman Slashes Guidant Rating


Goldman Sachs removed Guidant Corp. (GDT) from its recommended list and now rates the shares market perform. Goldman also trimmed estimates.

Analyst Lawrence Keusch says while stent sales were in line with his forecast, defibrillators came in a bit lower. More important is Guidant's downward Q2 guidance based on a tough quarter for defibrillators due to Prizm's recall and greater-than-expected stent competition. He notes his investment thesis is predicated on Guidant maintaining its base business until FDA clearance of the company's congestive heart-failure device (Contac).

Keusch says it now looks like the base business may erode further. He sees little upside in the near term. Keusch cut the $1.78 2001 EPS estimate to $1.63 and cut the $2.11 2002 estimate to $1.93.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus